Introduction Verzenio is the brand name of abemaciclib, an oral targeted anticancer drug used in selected patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. Pharmacologically, Verzenio belongs to the cyclin-dependent kinase 4 and 6 inhibitor class, commonly called CDK4/6 inhibitors. CDK4 and CDK6 are key enzymes that regulate progression of cells … Read more
Introduction Abemaciclib is an oral targeted anticancer drug used mainly in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer. It is marketed under the brand name Verzenio. Pharmacologically, abemaciclib belongs to the cyclin-dependent kinase 4 and 6 inhibitor class, commonly abbreviated as CDK4/6 inhibitors. CDK4 and CDK6 are important enzymes involved in cell-cycle … Read more
Introduction Ibrance is the brand name of palbociclib, an oral targeted anticancer drug belonging to the class of cyclin-dependent kinase 4 and 6 inhibitors, commonly called CDK4/6 inhibitors. It is mainly used in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced or metastatic breast cancer. Ibrance is pharmacologically important because it targets a key … Read more
Introduction Kisqali is the brand name of ribociclib, an oral targeted anticancer drug used in hormone receptor-positive, HER2-negative breast cancer. It belongs to the class of cyclin-dependent kinase 4 and 6 inhibitors, commonly called CDK4/6 inhibitors. Kisqali is important in oncology pharmacology because it targets the cell cycle machinery that allows cancer cells to divide … Read more
